$TLSI Cashflow Statement | Understand Stock

$TLSI

$3.80 +$0.18 (4.97%) Close

$TLSI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net income
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of warrant liabilities
Transaction costs associated with the Initial Public Offering
Formation cost paid by sponsor in exchange for issuance of founder shares
Interest earned on cash and investments held in Trust Account
Depreciation
Non-cash lease expense
Change in fair value of SEPA, warrant and revenue base redemption liabilities
Change in fair value of contingent earnout liability
Change in fair value of Initial OrbiMed Warrant and revenue base redemption liabilities
Non-cash interest expense
Loss on equity issuance
Extinguishment of tranche liability
PIK interest
Stock-based compensation expense
Allowance for credit losses
Loss on disposal of property and equipment
Loss on impairment of intangible assets
Amortization of debt issuance costs
Milestone payment to Dynavax
Changes in operating assets and liabilities:
Accounts receivable
Inventory, net
Prepaid expenses and other assets
Accounts payable and accrued expenses
Due to stockholders
Income taxes payable
Operating lease right-of-use assets
Deposits
Operating lease liabilities
Trade payables and accrued liabilities

Net cash used in operating activities

Investment of cash into Trust Account
Cash withdrawn from Trust Account to pay franchise and income taxes
Cash withdrawn from Trust Account in connection with redemptions
Cash flows from investing activities
Purchases of property and equipment
Milestone payment to Dynavax
Cash paid for intellectual property and licenses
Proceeds from disposal of property and equipment
Net cash used in investing activities
Proceeds from promissory note
Proceeds from promissory note - related party
Proceeds from Convertible Promissory Note - related party
Extension capital contribution from TriSalus
Redemptions of Class A common stock

Cash flows from financing activities
Proceeds from the issuance of preferred stock
Proceeds from the issuance of common stock
Proceeds from exercise of preferred stock warrants
Purchase of common stock warrants
Common stock issuance costs
Proceeds from the exercise of stock options for common stock
Proceeds from the issuance of common stock through employee stock purchase plan
Payments on finance lease liabilities
Net cash provided by financing activities
Increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental disclosures of cash flow information
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of noncash items
Right-of-use assets obtained in exchange for new operating lease liabilities
Right-of-use assets obtained in exchange for new finance lease liabilities
Non-cash capital expenditures included in trade payables
Fixed asset purchase through exchange of finance lease right-of-use asset
Derecognition of finance lease right-of-use asset
Prepaid warrant issuance costs
Fair value of warrants issued with OrbiMed debt
Fair value of revenue base redemption liability related to OrbiMed debt
Non-cash interest expense
Transfer of warrant liability to common stock upon exercise of warrant
Transfer of warrant liability to preferred stock upon exercise of warrants

Comments